A Study of Personalized Neoantigen Cancer Vaccines
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03794128 |
Recruitment Status :
Recruiting
First Posted : January 4, 2019
Last Update Posted : August 13, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Non Small Cell Lung Cancer Colorectal Cancer Gastroesophageal Adenocarcinoma Urothelial Carcinoma Pancreatic Ductal Adenocarcinoma | Procedure: Blood collection for research (next-generation sequencing [NGS]) Procedure: Blood collection for research (HLA typing) |
Gritstone is developing two neoantigen-based cancer vaccines: the first is a patient-specific cancer vaccine that requires a manufacturing period for each patient and the second is an off-the-shelf cancer vaccine that targets shared neoantigens.
The process of generating a patient-specific neoantigen cancer vaccine involves multiple steps, including collection of patient tumor and blood specimens, performing next-generation sequencing (NGS), predicting the neoantigens to be included in the patient-specific vaccine, and the manufacture and release of the patient-specific vaccine. Gaining experience in managing the manufacturing process will provide important insights and experience regarding this process to be used in operationalizing future clinical trials.
Selecting patients who may be eligible to receive a shared neoantigen vaccine requires first identifying patients whose tumor possesses a neoantigen derived from an oncogenic mutation that is encoded by the vaccine, and then determining whether the patient expresses a matching HLA allele for antigen presentation.
Study participants will not receive any investigational treatment as part of this trial. Patients screened in this study may be able to enroll in a separate investigational treatment study sponsored by Gritstone Oncology, provided that the patient meets the specified eligibility criteria for that treatment study.
Study Type : | Observational |
Estimated Enrollment : | 140 participants |
Observational Model: | Case-Only |
Time Perspective: | Prospective |
Official Title: | An Observational Feasibility Study for the Production of a Patient-Specific Neoantigen Cancer Vaccine and Screening Study for a Shared Neoantigen Cancer Vaccine in Patients With Advanced Cancer |
Actual Study Start Date : | July 25, 2018 |
Estimated Primary Completion Date : | December 2019 |
Estimated Study Completion Date : | December 2019 |

Group/Cohort | Intervention/treatment |
---|---|
1 - patient-specific neoantigen cancer vaccine production |
Procedure: Blood collection for research (next-generation sequencing [NGS])
Participants will have whole blood collected for next-generation sequencing (NGS). Procedure: Blood collection for research (HLA typing) Participants will have whole blood collected for HLA typing. |
2 - shared neoantigen cancer vaccine screening |
Procedure: Blood collection for research (HLA typing)
Participants will have whole blood collected for HLA typing. |
- Group 1 only: Presence of neoantigens sufficient to warrant patient-specific vaccine manufacture [ Time Frame: At study enrollment ]
- Group 1 only: Percentage of patients for whom patient-specific vaccine is successfully manufactured (defined as meeting release criteria) [ Time Frame: Up to approximately 20 weeks ]
- Group 2 only: Percentage of patients with at least one of the twenty specified shared mutations contained in the expression cassette and a matching HLA allele for neoantigen presentation [ Time Frame: Up to approximately 2 weeks ]
Biospecimen Retention: Samples With DNA
- whole blood specimen, for HLA typing (all participants)
- FFPE tumor material from a biopsy or resection, for sequencing to identify tumor-specific mutations (Group 1 participants only)
- whole blood specimen, for sequencing of normal genome (Group 1 participants only)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Group 1 Inclusion Criteria:
- Provide a signed and dated informed consent form prior to initiation of study-specific procedures
-
Patients with the indicated advanced or metastatic solid tumor as follows:
- NSCLC who have received ≤ 1 cycle of systemic treatment with cytotoxic, platinum-based chemotherapy (Note: patients with NSCLC who are receiving pembrolizumab monotherapy as first line systemic monotherapy are eligible)
- GEA who have received ≤ 1 cycle of systemic treatment with cytotoxic, platinum-based chemotherapy
- mUC who have received ≤ 1 cycle of systemic treatment with cytotoxic, platinum-based chemotherapy
- CRC-microsatellite stable (MSS) who have received ≤ 1 cycle of second line systemic therapy including a fluoropyrimidine and oxaliplatin or irinotecan (Note: patients receiving first-line systemic therapy are eligible)
- 18 years of age or older
- ECOG Performance Status 0 or 1
- Available FFPE tumor specimen for sequencing and neoantigen selection
- Measurable disease according to RECIST v1.1 Have adequate organ function, as measured by laboratory values (criteria listed in protocol)
Group 1 Exclusion Criteria:
-
Tumors with genetic characteristics as follows:
- For NSCLC, patients with a known driver genomic alteration in EGFR, ALK, ROS1, RET, or TRK
- For CRC or GEA, patients with MSI disease
- For CRC, patients with a known BRAF mutation or patients with peritoneal carcinomatosis
Group 2 Inclusion Criteria:
- Provide a signed and dated informed consent form prior to initiation of study-specific procedures
- Patient's tumor possesses one of the mutations listed in the clinical study protocol, as determined per local institutional standard
-
Patients with an advanced or metastatic solid tumor as follows:
- MSS-CRC who are currently receiving systemic treatment with a fluoropyrimidine and oxaliplatin or irinotecan that may include a VEGF or EGFR targeting therapy as their first-line or second-line therapy for metastatic disease
- NSCLC who are currently receiving systemic treatment with cytotoxic, platinum-based chemotherapy in combination with an anti-PD-(L)1 antibody
- PDA who are currently receiving systemic cytotoxic chemotherapy as their first-line therapy for metastatic disease
Group 2 Exclusion Criteria
- Patients with MSI disease
- Patients with NSCLC with a known driver genomic alteration in EGFR, ALK, ROS1, RET, or TRK
Complete inclusion and exclusion criteria are listed in the clinical study protocol.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03794128
Contact: Andy Ferguson | 857-327-9816 | aferguson@gritstone.com | |
Contact: Cynthia Voong | 510-871-6104 | cvoong@gritstone.com |
United States, Illinois | |
University of Chicago Medicine Comprehensive Cancer Center | Recruiting |
Chicago, Illinois, United States, 60637 | |
Contact: Aurelie Desgardin adesgard@medicine.bsd.uchicago.edu | |
United States, New York | |
Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center | Recruiting |
New York, New York, United States, 10032 | |
Contact: Raquel Gindi-Kolker rg3223@cumc.columbia.edu | |
United States, Ohio | |
The Ohio State University Comprehensive Cancer Center | Recruiting |
Columbus, Ohio, United States, 43210 | |
Contact: Carly Pilcher carly.pilcher@osumc.edu | |
United States, Tennessee | |
Tennessee Oncology | Recruiting |
Nashville, Tennessee, United States, 37203 | |
Contact: Dee McComb davinia.mccomb@sarahcannon.com | |
Contact cann.researchreferrals@scresearch.net | |
United States, Virginia | |
Virginia Cancer Specialists | Recruiting |
Fairfax, Virginia, United States, 22031 | |
Contact: Marcy Sullivan marcy.sullivan@usoncology.com |
Responsible Party: | Gritstone Oncology, Inc. |
ClinicalTrials.gov Identifier: | NCT03794128 History of Changes |
Other Study ID Numbers: |
GO-003 |
First Posted: | January 4, 2019 Key Record Dates |
Last Update Posted: | August 13, 2019 |
Last Verified: | August 2019 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
neoantigen cancer vaccine personalized neoantigen cancer vaccine |
Adenocarcinoma Carcinoma, Transitional Cell Neoplasms Carcinoma Neoplasms, Glandular and Epithelial |
Neoplasms by Histologic Type Vaccines Immunologic Factors Physiological Effects of Drugs |